Geron Corp - Company Profile
Powered by 
All the data and insights you need on Geron Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Geron Corp Strategy Report
- Understand Geron Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Geron Corp Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Geron Corp Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 08 Dec 2013 | Lorem |
| Geron’s phrasing in imetelstat myelofibrosis ASH abstract unusual - sources | 08 Nov 2013 | Juliana Wexler |
| Geron to discuss expanding imetelstat myelofibrosis trial with potential investigators at ASH - source | 07 Nov 2013 | Juliana Wexler |
| Neuralstem yet to confirm CRO for Phase I chronic spinal cord injury trial with neural stem cell product - CEO | 16 Jan 2013 | Casey McDonald |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer